Thyroid transcription factor-1, TTF-1, Nkx2.1, thyroid-specific enhancer-binding protein

A 38 kD homeodomain-containing nuclear transcription protein of the Nkx2 gene family59. The TTF-1 polypeptide of 371 amino acids have been highly conserved, sharing 98% identity with the rat TTF-1 polypeptide59. The homeobox gene HOXB3 (expressed in early mammalian embryogenesis in the anterior neuroectoderm, branchial arches and their derivatives, including the area of the thyroid primordia and thyroid gland) activates expression of TTF-156. TTF-1 in turn acts as a master regulator gene, binding to the promoters for surfactant apoproteins A57, B60 and C62, Clara cell-specific protein (mCC10)61 and T1a65. TTF-1 is also required for expression of thyroid-specific genes58. During embryogenesis, it is first expressed at the emergence of the laryngeotracheal diverticulum and is localised to the bronchial epithelium. Once the bronchial tree has developed, expression shifts to the peripheral airway epithelium, a pattern retained throughout life18.

The commercially available monoclonal antibody 8G7G3/163 can be used on formalin-fixed, paraffin-embedded tissues: this antibody has been used in most studies of TTF-1. A second monoclonal antibody, SPT24, appears to have greater sensitivity, at the expense of loss of specificity: see comparison of monoclonal antibodies. The monoclonal antibodies probably have greater sensitivity than the polyclonal antibody used in some early studies.

Staining for TTF-1 is nuclear. Cases should be regarded as positive even if the nuclear staining is only focally present in the tumour (i.e. 1% to 10% of the tumour cells)23. In up to 10% of TTF-1-positive lung adenocarcinomas, staining is present in less than 10% of the tumour cells24,25. Even this focal staining is not encountered in adenocarcinomas of non-pulmonary and non-thyroid origin.

A rapid technique has been developed for use with intra-operative frozen sections37,86.

Cytoplasmic immunoreactivity for TTF-1 has been reported as useful in the diagnosis of hepatocellular carcinoma.

Immunohistochemical expression

TTF-1 is expressed in various normal tissues: follicular cells of the thyroid, type II epithelial cells of the alveoli4 and a subset of bronchiolar cells4, the anterior pituitary, parathyroid gland, parafollicular C-cells and in certain regions of the brain.

Non-neoplastic lung disease:

In infantile hyaline membrane disease with alveolar hemorrhage, oedema, or airway collapse, little or no TTF-1 is present except in open terminal airways. In bronchopulmonary dysplasia, TTF-1 is absent in areas of alveolar collapse or infection, being present in regenerating open airways64.

There is a case report of epithelial cyst of the cardiac papillary muscle positive for TTF-185.

Positivity has been reported in ciliated metaplasia in the stomach and in non-ciliated cells in atrophic gastritis93. This positivity has been attributed to gastric broncho-pulmonary transdetermination.

Tumours reference 5 reviews multiple papers up to 19994:



77% (2025/2631; 95% confidence interval 75.42% to 78.6%)

158/2082, 19/334, 70/976, 23/2612, 42/4715, 12/1516, 46/6418,  14/1719, 37/4320, 24/3522, 11/1123, 67/9824 , 30/4025, 37/5026, 46/6418, 110/12831, 37/5035, 51/7538, 27/3039, 220/23145, 42/5046, 13/1647, 15/1748, 35/4649, 8/1350, 5/663, 16/2166, 12/1867, 3/1668, 27/3469, 10/1171, 8/972 , 21/3973, 31/4275, 31/4277, 46/5580 , 29/4082, 41/5084, 12/2287, 42/4678, 4/1590, 11/1191, 22/3092, 4/10102, 13/14103, 5/8104, 20/28105 , 18/21106, 69/95114, 134/200115,  127/158116, 30/52

bronchoalveolar carcinoma

25/292, 25/2820, 34/5035, 8/1636, 11/1439, 42/6742, 23/2345, 26/29115

small cell carcinoma

84.4%(448/527; 95% confidence interval 82% to 87%)

113/1205, 30/377, 27/288, 43/529, 1/415,11/1218, 6/723, 30/3724, 47/5532, 24/3039, 3/540, 20/2141, 19/3645, 20/2252, 10/1266, 2/568, 6/771, 23/2877, 27/3088, 3/378, 10/1090, 13/1391, 38/41104, 35/36108, 28/33109, 1/3114, 1/1115

squamous cell carcinoma

8.5%(79/930; 95% confidence interval 6.7% to 10.3%),

excluding one anomalous paper115, 6.1% (95% confidence interval 4.4% to 7.7%)

0/1012, 20/2015, 6/1196, 0/1212, 1/715, 0/323, 0/2024 , 0/1030, 0/2931, 9/4338, 1/3039, 4/9945, 0/1049, 3/866 0/868, 3/871, 0%77, 4/778, 3/1390, 0/1291, 0/39102, 0/5103, 1/9104, 13/60105, 0/48114, 30/122115, 0/39116 , 1/35119

basaloid squamous cell carcinoma


basaloid carcinoma


adenosquamous carcinoma

1/339, 2/26, 2/10115

large cell carcinoma

25% (50/197; 95% confidence interval 19% to 31%)

16/612, 6/625, 0/26, 15/1923, 8/2024 , 3/1030, 0/131, 0/238, 4/2539, 26%2, 1/668, 0/190, 5/991, 4/9114, 16/37115

large cell neuroendocrine carcinoma

50.6% (83/164; 95% confidence interval 43% to 58%).

2/47, 6/85, 18/4412, 2/424 , 2/231, 31/6432, 6/1039, 6/840, 6/841, 6/1676, 2/3103, 4/10107, 3/5115

pleomorphic carcinoma

~55%, 0/2345

lymphoepithelioma-like carcinoma


Carcinoma not otherwise specified

21/2855, 1/371, 13/3088, 3/12114

Pulmonary blastoma


Pulmonary tumourlet (neuroendocrine cell hyperplasia)

0/3832, 8/1176, 0/1532 , 0/2332

typical carcinoid

4/97, 16/1710, 11/1613, 6/1224 , 1/131, 0/2732†, 6/2339, 18/5141, 0/845, 10/3676, 0/890, 6/12113, 1/2114

atypical carcinoid

2/37, 3/310, 2/324 , 0/2332†, 9/941, 0/345, 5/1776, 2/3113, 1/1114

metastatic pulmonary carcinoid


sclerosing haemangioma

36/373, 16/1614, 39/4445

pulmonary papillary adenoma

1/127, 2/2111

alveolar adenoma


inflammatory myofibroblastic tumour


Extra-pulmonary adenocarcinoma (excluding thyroid)


Extra-pulmonary small cell carcinoma (excluding skin)

36% (42/114), various sites

Extra-pulmonary squamous cell carcinoma

0/323, 0/1171

Extra-pulmonary large cell neuroendocrine carcinoma

1/4 (various sites)7, 0/376, 1/195

Extra-pulmonary carcinoid

1% (1/207, 0/5010, 0/4911, 1/4613), 0/67, 0/270, 1/274, 0/2876 , 0/2117

Extra-pulmonary endocrine tumours

parathyroid adenoma


pituitary adenoma


pancreatic endocrine tumour

0/1010, 0/1511, 0/12613


0/2111, 0/196

adrenocortical carcinoma




Malignant mesothelioma

0% ( 0/952, 0/244, 0/1415, 0/4122, 0/60)26, 0/50, 0/1269, 0/678, 0/1592, 0/38114



13/155, 5/510, 10/1228, 6/6112

follicular carcinoma

14/145, 5/510, 4/428, 3/3, 10/10112

papillary carcinoma

27/285, 5/510, 8/828, 7/7, 3/363, 10/10112, 37/38114

Hurtle cell carcinoma

1/55, 2/628

Insular carcinoma


medullary carcinoma

15/165,7, 10/1010, 8/811, 1/228

poorly differentiated carcinoma

0/23, 6/728

anaplastic carcinoma

2/3517, 0/85, 2/510, 1/428, 0/4112

spindle epithelial tumor with thymus-like differentiation (SETTLE)


Thyroid-like nasopharyngeal papillary adenocarcinoma

2/279, 1/189, 3/398

Struma ovarii


Thymic neoplasms

0/201, 0/310, 0/5729, 0/3030, 1118

Renal tumours



metanephric adenoma


cystic nephroma


Testicular choriocarcinoma





synovial sarcoma



Primary brain tumours

2/7353, 0/3253, 0/5081, dependent on clone used101


0/115, 0/67, 0/499, 1/70100, 5/73100

Merkel cell carcinoma of skin

0/61, 0/215, 0/167, 0/239

Among primary pulmonary adenocarcinomas, there is a higher rate of positivity in tumours thought to be derived from the terminal respiratory unit (TRU, in the WHO classification these are most non-mucinous bronchioloalveolar, mixed bronchioloalveolar and acinar subtypes and some papillary subtypes); 42/48 with TRU morphology were positive, as against 4/16 with non-TRU morphology18. In one paper, immunoreactivity in adenocarcinomas is more common in females (27/31 positive) than males (19/33 positive) and in nonsmokers (26/31 positive) than in smokers (20/33 positive), in p53-negative tumours and in retinoblastoma-positive tumours18. However, another reports that no associations were noted with gender6. A comparison of primary tumours and their metastases showed no tendency to loss of staining during dissemination18.

Two studies showed postivity for TTF-1 in conventional pulmonary adenocarcinomas to be a significant independent predictor of survival35,38. A second study Another found a tendency (p=0.096) to an association between TTF-1 positivity and better survival34, along with a negative correlation with Ki-67 proliferative activity (p=0.003): another found no association of TTF-1 positivity with survival31.

When large cell neuroendocrine carcinoma of the lung is a component of a combined tumour, it adopts the TTF-1 reactivity of the other component, positive where it is small cell carcinoma and with some adenocarcinomas, negative where it is squamous cell carcinoma12,32. In one of these studies, three combined small cell / squamous cell carcinomas showed negativity of both components32.

†The inconsistent results in carcinoids, typical and atypical, may be due to the use of polyclonal antibodies in early studies, misinterpretation of granular cytoplasmic staining that overlaps the nucleus, and the misclassification of large cell neuroendocine carcinomas at atypical carcinoids prior to the 1999 WHO classification32.

Diagnostic utility


positive predictive value

negative predictive value

To differentiated pulmonary from extrapulmonary adenocarcinoma (best used in combination with cytokeratins 7 and 20)



To show tumour is an extra-pulmonary small cell carcinoma, not a Merkel cell carcinoma



 To show carcinoid is of pulmonary origin



Im the development of an algorithm to locate the primary site of adenocarcinomas, TTF-1 appears high in the decision tree78.


1 S Pomplun. Immunohistochemical markers in the differentiation of thymic and pulmonary neoplasms. Abstract 158, Pathological Society of Great Britain and Ireland January 2001.

2 A Khoor et al. Utility of surfactant protein B precursor and thyroid transcription factor 1 in differentiating adenocarcinoma of the lung from malignant mesothelioma. Human Pathology 1999;30:695-700.

3 M Devousassoux-Shisheboran et al. A clinicopathological study of 100 cases of pulmonary sclerosing hemangioma with immunohistochemical studies. Am J Surg Pathol 2000; 24: 906-916.

4 Di Loreto C et al. TTF-1 protein expression in pleural malignant mesotheliomas and adenocarcinomas of the lung. Cancer letters 1998;124:73-78.

5 Ordonez NG. Thyroid transcription factor-1 is a marker of lung and thyroid carcinomas. Advances in Anatomic Pathology 2000; 7(2): 123-127.

 6 Pelosi G et al. Immunoreactivity for thyroid transcription factor-1 in stage I non-small cell carcinomas of the lung. Am J Surg Pathol 2001;25:363-372.

7 Kaufmann O & Dietel M. Expression of thyroid transcription factor-1 in pulmonary and extrapulmonary small cell carcinomas and other neuroendocrine carcinomas of various primary sites. Histopathology 2000; 36: 415-420.

8 Ordonez NG. Value of thyroid transcription factor-1 immunostaining in distinguishing small cell lung carcinomas from other small cell carcinomas. Am J Surg Pathol 2000;24:1217-1223.

9 Cheuk W et al. Immunostaining for thyroid transcription factor-1 and cytokeratin 20 aids in the distinction of small cell carcinoma from Merkel cell carcinoma, but not pulmonary from extrapulmonary small cell carcinoma. Arch Pathol Lab Med 2001;125:228-231. FULL TEXT

10 Oliveira AM et al. Thyroid transcription factor-1 distinguishes metastatic pulmonary from well-differentiated neuroendocrine tumors of other sites. Am J Surg Pathol 2001;25:815-819.

11 Agoff, S. N., Lamps, L. W., Philip, A. T., Amin, M. B., Schmidt, R. A., True, L. D., Folpe, A. L. Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumours. Mod Pathol 2000;13:238-242.

12 Sturm, N., Lantuejoul, S., Laverriere, M. H., Papotti, M., Brichon, P. Y., Brambilla, C., Brambilla, E. Thyroid transcription factor 1 and cytokeratins 1, 5, 10, 14 (34betaE12) expression in basaloid and large-cell neuroendocrine carcinomas of the lung. Hum Pathol 2001;32:918-925.

13 Cai, Y. C., Banner, B., Glickman, J., Odze, R. D. Cytokeratin 7 and 20 and thyroid transcription factor 1 can help distinguish pulmonary from gastrointestinal carcinoid and pancreatic endocrine tumors. Human Pathol 2001;32:1087-1093

14 Chan, A. C., Chan, J. K. Pulmonary sclerosing hemangioma consistently expresses thyroid transcription factor-1 (TTF-1): a new clue to its histogenesis Am J Surg Pathol 2000;24:1531-1536.

15 Hecht, J. L., Pinkus, J. L., Weinstein, L. J., Pinkus, G. S. The value of thyroid transcription factor-1 in cytologic preparations as a marker for metastatic adenocarcinoma of lung origin Am J Clin Pathol 2001;116:483-488.

16 Amin, M. B., Tamboli, P., Merchant, S. H., Ordonez, N. G., Ro, J., Ayala, A. G., Ro, J. Y. Micropapillary component in lung adenocarcinoma: a distinctive histologic feature with possible prognostic significance. Am J Surg Pathol 2002;26:358-364.

17 Miettinen, M., Franssila, K. O. Variable expression of keratins and nearly uniform lack of thyroid transcription factor 1 in thyroid anaplastic carcinoma. Hum Pathol 2000;31:1139-45.

18 Yatabe, Y., Mitsudomi, T. and Takahashi, T. TTF-1 expression in pulmonary adenocarcinomas. Am J Surg Pathol 2002;26:767-73.

19 Merchant, S.H., Amin, M.B., Tamboli, P., Ro, J., Ordonez, N.G., Ayala, A.G., Czerniak, B.A. and Ro, J.Y. Primary signet-ring cell carcinoma of lung: immunohistochemical study and comparison with non-pulmonary signet-ring cell carcinomas. Am J Surg Pathol 2001;25:1515-9.

20 Barbareschi, M., Murer, B., Colby, T.V., Chilosi, M., Macri, E., Loda, M. and Doglioni, C. CDX-2 Homeobox Gene Expression Is a Reliable Marker of Colorectal Adenocarcinoma Metastases to the Lungs. Am J Surg Pathol 2003;27:141-9.

21 Rossi, G., Cavazza, A., Sturm, N., Migaldi, M., Facciolongo, N., Longo, L., Maiorana, A. and Brambilla, E. Pulmonary carcinomas with pleomorphic, sarcomatoid, or sarcomatous elements: a clinicopathologic and immunohistochemical study of 75 cases. Am J Surg Pathol 2003;27:311-24.

22 Abutaily, A.S., Addis, B.J. and Roche, W.R. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies. J Clin Pathol 2002;55:662-8.

23 Srodon, M. and Westra, W.H. Immunohistochemical staining for thyroid transcription factor-1: a helpful aid in discerning primary site of tumor origin in patients with brain metastases. Hum Pathol 2002;33:642-5.

24 Kaufmann, O. and Dietel, M. Thyroid transcription factor-1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B. Histopathology 2000;36:8-16.

25 Ordonez, N.G. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma. Am J Surg Pathol 2000;24:598-606.

26 Ordonez, N. G. (2003). "The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma." Am J Surg Pathol 27(8): 1031-51.

27 Sheppard, M. N., L. Burke, et al. (2003). "TTF-1 is useful in the diagnosis of pulmonary papillary adenoma." Histopathology 43(4): 404-5.

28 Bejarano, P. A., Y. E. Nikiforov, et al. (2000). "Thyroid transcription factor-1, thyroglobulin, cytokeratin 7, and cytokeratin 20 in thyroid neoplasms." Appl Immunohistochem Mol Morphol 8(3): 189-94.

29 Pan, C. C., P. C. Chen, et al. (2003). "Expression of calretinin and other mesothelioma-related markers in thymic carcinoma and thymoma." Hum Pathol 34(11): 1155-62.

30 Pomplun, S., A. C. Wotherspoon, et al. (2002). "Immunohistochemical markers in the differentiation of thymic and pulmonary neoplasms." Histopathology 40(2): 152-8.

31 Stenhouse, G., N. Fyfe, et al. (2004). "Thyroid transcription factor 1 in pulmonary adenocarcinoma." J Clin Pathol 57(4): 383-7.

32 Sturm, N., G. Rossi, et al. (2002). "Expression of thyroid transcription factor-1 in the spectrum of neuroendocrine cell lung proliferations with special interest in carcinoids." Hum Pathol 33(2): 175-82.

33 Quddus MR et al. Expression of TTF-1 in primary ovarian surface epithelial carcinomas: a study of 53 cases. Modern Pathology 2004 17(1):211A.

34 Myong, N. H. (2003). "Thyroid transcription factor-1 (TTF-1) expression in human lung carcinomas: its prognostic implication and relationship with wxpressions of p53 and Ki-67 proteins." J Korean Med Sci 18(4): 494-500.

35 Saad, R. S., Y. L. Liu, et al. (2004). "Prognostic significance of thyroid transcription factor-1 expression in both early-stage conventional adenocarcinoma and bronchioloalveolar carcinoma of the lung." Hum Pathol 35(1): 3-7.

36 Simsir, A., X. J. Wei, et al. (2004). "Differential expression of cytokeratins 7 and 20 and thyroid transcription factor-1 in bronchioloalveolar carcinoma: an immunohistochemical study in fine-needle aspiration biopsy specimens." Am J Clin Pathol 121(3): 350-7.

37 Camilleri-Broet, S., M. Alifano, et al. (2004). "Peroperative frozen section analysis of TTF-1 antigen expression." J Clin Pathol 57(1): 98-100. FULL TEXT

38 Tan, D., Q. Li, et al. (2003). "Thyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: a high-throughput tissue microarray and immunohistochemistry study." Hum Pathol 34(6): 597-604.

39 Jerome Marson, V., J. Mazieres, et al. (2004). "Expression of TTF-1 and cytokeratins in primary and secondary epithelial lung tumours: correlation with histological type and grade." Histopathology 45(2): 125-34.

40 Barbareschi, M., C. Roldo, et al. (2004). "CDX-2 homeobox gene product expression in neuroendocrine tumors: its role as a marker of intestinal neuroendocrine tumors." Am J Surg Pathol 28(9): 1169-76.

41 Folpe AL, Gown AM, Lamps LW, et al. Thyroid transcription factor-1: immunohistochemical evaluation in pulmonary neuroendocrine tumors. Mod Pathol 1999; 12:5-8

42 Lau SK, Desrochers MJ,Luthringer DJ Expression of thyroid transcription factor-1, cytokeratin 7, and cytokeratin 20 in bronchioloalveolar carcinomas: an immunohistochemical evaluation of 67 cases. Mod Pathol 2002; 15:538-42

43 Lau SK, Luthringer DJ,Eisen RN Thyroid transcription factor-1: a review. Appl Immunohistochem Mol Morphol 2002; 10:97-102

44 Zamecnik J,Kodet R Value of thyroid transcription factor-1 and surfactant apoprotein A in the differential diagnosis of pulmonary carcinomas: a study of 109 cases. Virchows Arch 2002; 440:353-61

45 Chang YL, Lee YC, Liao WY, et al. The utility and limitation of thyroid transcription factor-1 protein in primary and metastatic pulmonary neoplasms. Lung Cancer 2004; 44:149-57

46 Moldvay J, Jackel M, Bogos K, et al. The role of TTF-1 in differentiating primary and metastatic lung adenocarcinomas. Pathol Oncol Res 2004; 10:85-8

47 Jang KY, Kang MJ, Lee DG, et al. Utility of thyroid transcription factor-1 and cytokeratin 7 and 20 immunostaining in the identification of origin in malignant effusions. Anal Quant Cytol Histol 2001; 23:400-4

48 Ng WK, Chow JC,Ng PK Thyroid transcription factor-1 is highly sensitive and specific in differentiating metastatic pulmonary from extrapulmonary adenocarcinoma in effusion fluid cytology specimens. Cancer 2002; 96:43-8

49 Bejarano PA, Baughman RP, Biddinger PW, et al. Surfactant proteins and thyroid transcription factor-1 in pulmonary and breast carcinomas. Mod Pathol 1996; 9:445-52

50 Reis-Filho JS, Carrilho C, Valenti C, et al. Is TTF1 a good immunohistochemical marker to distinguish primary from metastatic lung adenocarcinomas? Pathol Res Pract 2000; 196:835-40

51 King JE, Thatcher N, Pickering CA, et al. Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data. Histopathology 2006; 48:223-32

52 Carlson JW, Nucci MR, Brodsky J, et al. Biomarker-assisted diagnosis of ovarian, cervical and pulmonary small cell carcinomas: the role of TTF-1, WT-1 and HPV analysis. Histopathology 2007; 51:305-12

53 Zamecnik J, Chanova M,Kodet R. Expression of thyroid transcription factor 1 in primary brain tumours. J Clin Pathol 2004; 57:1111-3

54 Zhang GQ, Fang XZ, Wang BQ, et al. [Clinicopathological and immunohistochemical features of pulmonary blastoma: analysis of 4 cases and review of the literature]. Zhonghua Yi Xue Za Zhi 2007; 87:1040-2

55 Chuang WY, Yeh CJ, Chu PH, et al. Expression of thyroid transcription factor-1 in brain metastases: a useful indicator of pulmonary origin. J Clin Neurosci 2008; 15:643-6

56 Guazzi S, Lonigro R, Pintonello L, et al. The thyroid transcription factor-1 gene is a candidate target for regulation by Hox proteins. Embo J 1994; 13:3339-47

57 Bruno MD, Bohinski RJ, Huelsman KM, et al. Lung cell-specific expression of the murine surfactant protein A (SP-A) gene is mediated by interactions between the SP-A promoter and thyroid transcription factor-1. J Biol Chem 1995; 270:6531-6

58 Saiardi A, Tassi V, De Filippis V, et al. Cloning and sequence analysis of human thyroid transcription factor 1. Biochim Biophys Acta 1995; 1261:307-10

59 Ikeda K, Clark JC, Shaw-White JR, et al. Gene structure and expression of human thyroid transcription factor-1 in respiratory epithelial cells. J Biol Chem 1995; 270:8108-14

60 Yan C, Sever Z,Whitsett JAç Upstream enhancer activity in the human surfactant protein B gene is mediated by thyroid transcription factor 1. J Biol Chem 1995; 270:24852-7

61 Ray MK, Chen CY, Schwartz RJ, et al. Transcriptional regulation of a mouse Clara cell-specific protein (mCC10) gene by the NKx transcription factor family members thyroid transciption factor 1 and cardiac muscle-specific homeobox protein (CSX). Mol Cell Biol 1996; 16:2056-64

62 Kelly SE, Bachurski CJ, Burhans MS, et al. Transcription of the lung-specific surfactant protein C gene is mediated by thyroid transcription factor 1. J Biol Chem 1996; 271:6881-8

63 Holzinger A, Dingle S, Bejarano PA, et al. Monoclonal antibody to thyroid transcription factor-1: production, characterization, and usefulness in tumor diagnosis. Hybridoma 1996; 15:49-53

64 Stahlman MT, Gray ME,Whitsett JA Expression of thyroid transcription factor-1(TTF-1) in fetal and neonatal human lung. J Histochem Cytochem 1996; 44:673-8

65 Ramirez MI, Rishi AK, Cao YX, et al. TGT3, thyroid transcription factor I, and Sp1 elements regulate transcriptional activity of the 1.3-kilobase pair promoter of T1alpha, a lung alveolar type I cell gene. J Biol Chem 1997; 272:26285-94

66 Harlamert HA, Mira J, Bejarano PA, et al. Thyroid transcription factor-1 and cytokeratins 7 and 20 in pulmonary and breast carcinoma. Acta Cytol 1998; 42:1382-8

67 Bohinski RJ, Bejarano PA, Balko G, et al. Determination of lung as the primary site of cerebral metastatic adenocarcinomas using monoclonal antibody to thyroid transcription factor-1. J Neurooncol 1998; 40:227-31

68 Chhieng DC, Cangiarella JF, Zakowski MF, et al. Use of thyroid transcription factor 1, PE-10, and cytokeratins 7 and 20 in discriminating between primary lung carcinomas and metastatic lesions in fine-needle aspiration biopsy specimens. Cancer 2001; 93:330-6 FULL TEXT

69 Afify AM,al-Khafaji BM. Diagnostic utility of thyroid transcription factor-1 expression in adenocarcinomas presenting in serous fluids. Acta Cytol 2002; 46:675-8

70 Hamazaki S, Okino T, Tsukayama C, et al. Expression of thyroid transcription factor-1 in strumal carcinoid and struma ovarii: an immunohistochemical study. Pathol Int 2002; 52:458-62

71 Roh MS,Hong SH. Utility of thyroid transcription factor-1 and cytokeratin 20 in identifying the origin of metastatic carcinomas of cervical lymph nodes. J Korean Med Sci 2002; 17:512-7 FULL TEXT

72 Romeike BF,Feiden W. [Diagnostic value of the monoclonal antibody to thyroid transcription factor -1(TTF-1) in CNS metastases. An immunohistochemical study of 65 cases]. Pathologe 2002; 23:292-6

73 Gomez-Fernandez C, Jorda M, Delgado PI, et al. Thyroid transcription factor 1: a marker for lung adenoarinoma in body cavity fluids. Cancer 2002; 96:289-93

74 Martignoni G,Eble JN Carcinoid tumors of the urinary bladder. Immunohistochemical study of 2 cases and review of the literature. Arch Pathol Lab Med 2003; 127:e22-4 FULL TEXT

75 Zou SM, Lin DM, Lu N, et al. [Use of thyroid transcription factor-1, surfacfant protein-B, cytokeratin 7 and cytokeratin 20 in discrimination between primary and metastatic adenocarcinoma of lung]. Zhonghua Yi Xue Za Zhi 2003; 83:1350-2

76 Du EZ, Goldstraw P, Zacharias J, et al. TTF-1 expression is specific for lung primary in typical and atypical carcinoids: TTF-1-positive carcinoids are predominantly in peripheral location. Hum Pathol 2004; 35:825-31

77 Lin DM, Zou SM, Lu N, et al. [TTF-1 expression and its diagnostic application in lung carcinomas]. Zhonghua Zhong Liu Za Zhi 2004; 26:615-7

78 Dennis JL, Hvidsten TR, Wit EC, et al. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res 2005; 11:3766-72 FULL TEXT

79 Carrizo F,Luna MA. Thyroid transcription factor-1 expression in thyroid-like nasopharyngeal papillary adenocarcinoma: report of 2 cases. Ann Diagn Pathol 2005; 9:189-92

80 Lau SK, Chu PG,Weiss LM. Immunohistochemical expression of estrogen receptor in pulmonary adenocarcinoma. Appl Immunohistochem Mol Morphol 2006; 14:83-7

81 Prok AL,Prayson RA. Thyroid transcription factor-1 staining is useful in identifying brain metastases of pulmonary origin. Ann Diagn Pathol 2006; 10:67-71

82 Su YC, Hsu YC, Chai CY. Role of TTF-1, CK20, and CK7 immunohistochemistry for diagnosis of primary and secondary lung adenocarcinoma. Kaohsiung J Med Sci 2006; 22:14-9 FULL TEXT

83 Satoh S, Toda S, Narikawa K, et al. Spindle epithelial tumor with thymus-like differentiation (SETTLE): youngest reported patient. Pathol Int 2006; 56:563-7

84 Jan IS, Chung PF, Weng MH, et al. Utility of thyroid transcription factor-1 expression in the differential diagnosis of metastatic adenocarcinoma of serous effusion specimens prepared using the cell transfer technique. J Formos Med Assoc 2006; 105:695-700

85 Soilleux EJ,Davies DR Epithelial cyst of the cardiac papillary muscle: case report and review of the literature. J Clin Pathol 2006; 59:1203-5

86 Butcher DN, Goldstraw P, Ladas G, et al. Thyroid transcription factor 1 immunohistochemistry as an intraoperative diagnostic tool at frozen section for distinction between primary and secondary lung tumors. Arch Pathol Lab Med 2007; 131:582-7 FULL TEXT

87 Strickland-Marmol LB, Khoor A, Livingston SK, et al. Utility of tissue-specific transcription factors thyroid transcription factor 1 and Cdx2 in determining the primary site of metastatic adenocarcinomas to the brain. Arch Pathol Lab Med 2007; 131:1686-90 FULL TEXT

88 Lin X, Saad RS, Luckasevic TM, et al. Diagnostic value of CDX-2 and TTF-1 expressions in separating metastatic neuroendocrine neoplasms of unknown origin. Appl Immunohistochem Mol Morphol 2007; 15:407-14

89 Wu PY, Huang CC, Chen HK, et al. Adult thyroid-like low-grade nasopharyngeal papillary adenocarcinoma with thyroid transcription factor-1 expression. Otolaryngol Head Neck Surg 2007; 137:837-8

90 Fabbro D, Di Loreto C, Stamerra O, et al. TTF-1 gene expression in human lung tumours. Eur J Cancer 1996; 32A:512-7

91 Johansson L. Histopathologic classification of lung cancer: Relevance of cytokeratin and TTF-1 immunophenotyping. Ann Diagn Pathol 2004; 8:259-67

92 Bakir K, Kocer NE, Deniz H, et al. TTF-1 and surfactant-B as co-adjuvants in the diagnosis of lung adenocarcinoma and pleural mesothelioma. Ann Diagn Pathol 2004; 8:337-41

93 Rau T, Dimmler A, Hafner M, et al. Aberrant expression of TTF-1 and forkhead factor HFH-4 in atrophic gastritis and ciliated metaplasia suggests gastric broncho-pulmonary transdetermination. J Pathol 2005; 206:383-7

94 Bisceglia M, Ragazzi M, Galliani CA, et al. TTF-1 expression in nephroblastoma. Am J Surg Pathol 2009; 33:454-61

95 McCluggage WG, Sargent A, Bailey A, et al. Large cell neuroendocrine carcinoma of the uterine cervix exhibiting TTF1 immunoreactivity. Histopathology 2007; 51:405-7

96 Corrado S, Montanini V, De Gaetani C, et al. Primary paraganglioma of the thyroid gland. J Endocrinol Invest 2004; 27:788-92

97 Agaimy A,Wunsch PH. Unexpected and potentially misleading TTF-1 expression: a word of caution. Virchows Arch 2006; 449:603-5

98 Zeizafoun N EG, Wenig BM. Thyroid transcription factor 1 (TTF-1) immunoreactivity in low-grade nasopharyngeal papillary adenocarcinoma (LCNPPA): a report of three cases. Mod Pathol 2007; 20:231A

99 Lewis JS, Ritter JH,El-Mofty S. Alternative epithelial markers in sarcomatoid carcinomas of the head and neck, lung, and bladder-p63, MOC-31, and TTF-1. Mod Pathol 2005; 18:1471-81 FULL TEXT

100 Plaza JA, Suster D,Perez-Montiel D. Expression of immunohistochemical markers in primary and metastatic malignant melanoma: a comparative study in 70 patients using a tissue microarray technique. Appl Immunohistochem Mol Morphol 2007; 15:421-5

101 Galloway M,Sim R. TTF-1 staining in glioblastoma multiforme. Virchows Arch 2007; 451:109-11

102 Kargi A, Gurel D,Tuna B. The diagnostic value of TTF-1, CK 5/6, and p63 immunostaining in classification of lung carcinomas. Appl Immunohistochem Mol Morphol 2007; 15:415-20

103 Rossi G, Marchioni A, Milani M, et al. TTF-1, cytokeratin 7, 34betaE12, and CD56/NCAM immunostaining in the subclassification of large cell carcinomas of the lung. Am J Clin Pathol 2004; 122:884-93 only cases verified by surgical resection have been tabulated here

104 Di Loreto C, Di Lauro V, Puglisi F, et al. Immunocytochemical expression of tissue specific transcription factor-1 in lung carcinoma. J Clin Pathol 1997; 50:30-2

105 Puglisi F, Barbone F, Damante G, et al. Prognostic value of thyroid transcription factor-1 in primary, resected, non-small cell lung carcinoma. Mod Pathol 1999; 12:318-24.

106 Anwar F, Schmidt R. Thyroid transcription factor-1 (TTF-1) distinguishes mesothelioma from pulmonary adenocarcinoma. Lab Invest 1999; 79:181A

107 Caccamo D, Linden M,Zarbo RJ Cytokeratin subtypes and thyroid transcription factor-1 (TTF-1) immunostaining in large cell neuroendocrine carcinoma of the lung (abstract 1222). Modern Pathology 2000; 13:207A

108 Byrd-Gloster AL, Khoor A, Glass LF, et al. Differential expression of thyroid transcription factor 1 in small cell lung carcinoma and Merkel cell tumor. Hum Pathol 2000; 31:58-62

109 Hanly AJ, Elgart GW, Jorda M, et al. Analysis of thyroid transcription factor-1 and cytokeratin 20 separates merkel cell carcinoma from small cell carcinoma of lung. J Cutan Pathol 2000; 27:118-20

110 Burke LM, Rush WI, Khoor A, et al. Alveolar adenoma: a histochemical, immunohistochemical, and ultrastructural analysis of 17 cases. Hum Pathol 1999; 30:158-67

111 Dessy E, Braidotti P, Del Curto B, et al. Peripheral papillary tumor of type-II pneumocytes: a rare neoplasm of undetermined malignant potential. Virchows Arch 2000; 436:289-95

112 Fabbro D, Di Loreto C, Beltrami CA, et al. Expression of thyroid-specific transcription factors TTF-1 and PAX-8 in human thyroid neoplasms. Cancer Res 1994; 54:4744-9 FULL TEXT

113 Saqi A, Alexis D, Remotti F, et al. Usefulness of CDX2 and TTF-1 in differentiating gastrointestinal from pulmonary carcinoids. Am J Clin Pathol 2005; 123:394-404 FULL TEXT

114 Bishop JA, Sharma R, Illei PB. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol. 2010 Jan;41(1):20-5. (TTF-1 clone 8G7G3/1 used, confirmed by author)

115 Anagnostou VK, Syrigos KN, Bepler G, Homer RJ, Rimm DL. Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma. J Clin Oncol. 2009 Jan 10;27(2):271-8. FULL TEXT

116 Yang M, Nonaka D. A study of immunohistochemical differential expression in pulmonary and mammary carcinomas. Mod Pathol. 2010 May;23(5):654-61. (with corrections to the paper provided by author)

117 Squillaci S, Marchione R, Piccolomini M, Colombo F, Bucci F, Bruno M, et al. Well-differentiated neuroendocrine carcinoma (malignant carcinoid) of the extrahepatic biliary tract: report of two cases and literature review. Apmis. 2010 Aug;118(8):543-56.

118 Yan B, Seng SC, Petersson F. Thymoma with nuclear expression of thyroid transcription factor-1: a potential diagnostic pitfall on core biopsy. Appl Immunohistochem Mol Morphol. 2011 Jan;19(1):76-81.

119 Kim JH, Choi YD, Lee JS, Lee JH, Nam JH, Choi C. Utility of thyroid transcription factor-1 and CDX-2 in determining the primary site of metastatic adenocarcinomas in serous effusions. Acta Cytol. 2010 May-Jun;54(3):277-82.

This page last revised 16.4.2011.

©SMUHT/PW Bishop